Eli Lilly Emerges as Leader in Competitive Weight-Loss Drug Market

Industry analysis highlights Eli Lilly's strategic advantages over rival Novo Nordisk in the rapidly expanding obesity treatment sector, positioning the pharmaceutical giant as the primary beneficiary of the GLP-1 gold rush.